Senti Bio公布了2025年第三季度的财务业绩,并确认将在12月的美国血液学会年会上发布其急性髓性白血病(Aml)Phase 1 Senti-202研究的下一批临床数据。
Senti Bio公布了2025年第三季度的财务业绩,并确认将在12月的美国血液学会年会上发布其急性髓性白血病(Aml)Phase 1 Senti-202研究的下一批临床数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.